Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy

Jasper Therapeutics, Inc. announced that it has entered into a non-exclusive research collaboration with AVROBIO, Inc. to evaluate the use of JSP191, Jasper’s anti-CD117 monoclonal antibody, as a targeted conditioning agent option for patients with Fabry disease and/or Gaucher disease type 1.